Erk Mapk Signaling In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The extracellular signal-regulated kinase (ERK) pathway, also known as the MAPK/ERK cascade, is a central signaling hub that regulates neuronal survival, synaptic plasticity, memory formation, and cellular proliferation. Unlike JNK and p38, which are primarily stress-activated kinases, the ERK pathway is typically activated by growth factors and mitogens. However, dysregulated ERK signaling contributes to neurodegeneration through complex mechanisms involving both pro-survival and pro-death functions.
flowchart TD
A[Growth Factors] --> B[RTK Activation] -->
A --> C[NGF, BDNF] -->
B --> D[Ras GTPase] -->
D --> E[Raf Kinases] -->
E --> F[MEK1/2] -->
F --> G[ERK1/2] -->
G --> H[ERK1<br>MAPK Pathway] -->
G --> I[ERK2<br>MAPK Pathway] -->
H --> J[MSK1/2 Activation] -->
H --> K[Elk-1 Phosphorylation] -->
I --> L[CREB Activation] -->
I --> M[c-Fos Expression] -->
J --> N[Histone H3<br>Phosphorylation] -->
K --> O[Immediate Early<br>Gene Transcription] -->
L --> O
M --> O
N --> P[Chromatin<br>Remodeling] -->
O --> Q[Synaptic<br>Plasticity] -->
P --> Q
| Component |
Aliases |
Function |
| Ras |
H-Ras, N-Ras, K-Ras |
Small GTPase, membrane anchor |
| Raf |
A-Raf, B-Raf, C-Raf |
MAPKKK, activates MEK |
| MEK1/2 |
MAPKK |
Dual-specificity kinase |
| ERK1/2 |
MAPK3, MAPK1 |
Tyrosine/threonine kinase |
| RSK |
p90RSK, MSK1/2 |
Ribosomal S6 kinase |
| Factor |
Target Genes |
Function |
| Elk-1 |
c-Fos, Egr-1 |
Immediate early genes |
| CREB |
BDNF, c-Fos, Arc |
Survival genes |
| c-Myc |
Cell cycle genes |
Growth regulation |
| c-Fos |
Various |
AP-1 component |
- Brain-Derived Neurotrophic Factor (BDNF): Primary neuronal activator
- Nerve Growth Factor (NGF): Survival signaling
- Glial Cell Line-Derived Neurotrophic Factor (GDNF): Dopaminergic neurons
- Insulin-like Growth Factor (IGF-1): Metabolic support
Despite its pro-survival reputation, ERK is paradoxically activated in neurodegenerative contexts:
- Amyloid-β: Triggers aberrant ERK activation
- Oxidative Stress: Adaptive and maladaptive responses
- Excitotoxicity: NMDA receptor-dependent activation
- Neuroinflammation: Cytokine-mediated signaling
flowchart LR
A[ERK Activation] --> B[CREB Phosphorylation] -->
B --> C[BDNF Expression] -->
C --> D[Synaptic Stability] -->
A --> E[RSK Activation] -->
E --> F[Bad Phosphorylation] -->
F --> G[Apoptosis Inhibition] -->
A --> G
D --> H[Neuronal Survival] -->
G --> H
- CREB-mediated transcription: BDNF, anti-apoptotic proteins
- RSK signaling: Phosphorylates Bad, inhibits apoptosis
- Synaptic plasticity: LTP formation, memory consolidation
- Stress response: Protective gene expression
- Sustained activation: Chronic ERK leads to toxicity
- Excitotoxicity amplification: NMDA-induced ERK activates pro-death programs
- Cell cycle re-entry: Post-mitotic neurons attempt division
- Transcriptional dysregulation: Abnormal gene expression
- Amyloid-β triggers pathological ERK activation
- Tau phosphorylation at multiple sites via ERK
- Synaptic plasticity deficits: Impaired LTP
- Memory consolidation failure: CREB dysfunction
- Neuronal cell cycle re-entry: ERK-driven
- GDNF signaling normally protects dopaminergic neurons
- α-Synuclein disrupts ERK signaling cascades
- Mitochondrial toxins cause aberrant ERK activation
- Neuroinflammation amplifies pathway dysregulation
- ERK activation in motor neurons
- Glial contributions via inflammatory signaling
- Mutant SOD1 alters MAPK signaling
- Excitotoxicity component
- Mutant huntingtin disrupts ERK nuclear signaling
- Transcriptional dysfunction through CREB
- Neurotrophic factor signaling impaired
- Adaptive stress response altered
- Biphasic response: Acute vs chronic activation has opposite effects
- Essential functions: Complete inhibition causes toxicity
- Cell-type specificity: Neurons vs glia have different needs
| Strategy |
Agent |
Stage |
Notes |
| MEK inhibitors |
Selumetinib |
Research |
Clinical for cancer |
| ERK inhibitors |
FR180204 |
Research |
Selectivity issues |
| RTK modulators |
Various |
Research |
Growth factor mimicry |
| Neurotrophic factors |
BDNF, GDNF |
Research |
Delivery challenges |
- Temporal modulation: Transient activation may be beneficial
- Cell-type targeting: Neuron-specific delivery
- Combination approaches: With antioxidants, neurotrophic factors
- Parallel survival signaling
- Cross-inhibition at multiple points
- Combined activation for neuroprotection
- Opposing effects on cell fate
- Stress vs growth factor signals
- Integration determines outcome
- Convergence on CREB
- Synergistic for memory formation
- Coordinate transcriptional programs
| Isoform |
Expression |
Specific Functions |
| ERK1 (p44) |
Ubiquitous |
Cognitive function |
| ERK2 (p42) |
Ubiquitous |
Development, plasticity |
| ERK5 |
Brain-enriched |
Long-term potentiation |
- Phospho-ERK levels: Pathway activation status
- RSK phosphorylation: Downstream signaling
- Gene expression signatures: CREB targets
- Isoform-specific roles: ERK1 vs ERK2 in neurons
- Spatiotemporal control: Subcellular signaling domains
- Neurotrophin optimization: BDNF mimetics
- Cell cycle modulation: Preventing re-entry
The study of Erk Mapk Signaling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Thomas GM, et al. ERK signaling in neuronal function. Nat Rev Neurosci. 2007.
- Samuels IS, et al. ERK/MAPK in neurodegeneration. Prog Neuropsychopharmacol Biol Psychiatry. 2009.
- Zhong J. ERK signaling. Encyclopedia of Neuroscience. 2010.
- Lee S, et al. Dual roles of ERK in neurodegeneration. Exp Neurobiol. 2020.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
4 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
67% |
| Mechanistic Completeness |
50% |
Overall Confidence: 34%